Nie Fang, Wang Ying, Shi Wanting, Zhu Liru, Hao Jing, Tao Rancen
Thoracic Oncology Department, Baotou Cancer Hospital, Baotou, Inner Mongolia, China.
Oncology and Palliative Care Department, Baotou Cancer Hospital, Baotou, Inner Mongolia, China.
Front Surg. 2024 Nov 22;11:1500593. doi: 10.3389/fsurg.2024.1500593. eCollection 2024.
A meta-analysis study was done to figure out how to predict the prognosis of people with resectable non-small-cell lung cancer (NSCLC) who had a significant pathological response following neoadjuvant immunotherapy.
Up until August 2024, a comprehensive literature study was completed, and 2,386 connected studies were revised. The 35 selected studies included 3,118 resectable non-small-cell lung tumor participants at the beginning of the study. Using dichotomous techniques and a fixed or random model, the odds ratio (OR) and 95% confidence intervals (CIs) were used to assess the prediction using significant pathological response following neoadjuvant immunotherapy in resectable NSCLC.
Individuals with resectable NSCLC had significantly higher major pathological response when comparing neoadjuvant chemo-immunotherapy to neoadjuvant chemotherapy (OR, 5.07; 95% CI, 4.09-6.27, < 0.001), objective response rate to non-objective response rate (OR, 7.02; 95% CI, 4.28-11.50, < 0.001), and programmed death-ligand 1 ≥1% to programmed death-ligand ≤1% (OR, 2.49; 95% CI, 1.44-4.30, = 0.001). However, no significant difference was found in major pathological response between stage III and stage I-II (OR, 1.43; 95% CI, 0.88-2.33, = 0.15), and squamous cell cancer and non-squamous cell cancer (OR, 1.35; 95% CI, 0.95-1.92, = 0.09) in individuals with resectable NSCLCs.
Individuals with resectable NSCLCs had significantly higher major pathological response when comparing neoadjuvant chemo-immunotherapy to neoadjuvant chemotherapy, objective response rate to non-objective response rate, and programmed death-ligand 1≥1% to programmed death-ligand 1 ≤1%, however, no significant difference was found between stage III and stage I-II, and squamous cell cancer and non-squamous cell cancer. To validate this discovery, more research is required since most of the selected studies had a low sample size, and caution must be implemented when interacting with its values.
开展了一项荟萃分析研究，以确定如何预测新辅助免疫治疗后出现显著病理反应的可切除非小细胞肺癌（NSCLC）患者的预后。
截至2024年8月，完成了一项全面的文献研究，共筛选了2386项相关研究。入选的35项研究在研究开始时纳入了3118例可切除非小细胞肺癌患者。采用二分法技术和固定或随机模型，使用比值比（OR）和95%置信区间（CIs）来评估新辅助免疫治疗后显著病理反应在可切除NSCLC中的预测价值。
在可切除NSCLC患者中，与新辅助化疗相比，新辅助化疗联合免疫治疗的主要病理反应显著更高（OR，5.07；95%CI，4.09 - 6.27，<0.001），客观缓解率与非客观缓解率之比（OR，7.02；95%CI，4.28 - 11.50，<0.001），以及程序性死亡配体1≥1%与程序性死亡配体1≤1%之比（OR，2.49；95%CI，1.44 - 4.30，=0.001）。然而，在可切除NSCLC患者中，III期与I-II期之间（OR，1.43；95%CI，0.88 - 2.33，=0.15）以及鳞状细胞癌与非鳞状细胞癌之间（OR，1.35；95%CI，0.95 - 1.92，=0.09）的主要病理反应无显著差异。
在可切除NSCLC患者中，与新辅助化疗相比，新辅助化疗联合免疫治疗的主要病理反应显著更高，客观缓解率与非客观缓解率之比以及程序性死亡配体1≥1%与程序性死亡配体1≤1%之比也显著更高，然而，III期与I-II期之间以及鳞状细胞癌与非鳞状细胞癌之间无显著差异。由于大多数入选研究样本量较小，需要更多研究来验证这一发现，在解读其结果时必须谨慎。
